Pharma R&D Sees Record Returns amidst Optimized Processes and External Collaborations
In a groundbreaking development, research by Deloitte’s Centre for Health Solutions reveals that 15 global pharmaceutical companies, including the 12 largest by market capitalization, are experiencing a surge in projected returns on investment (ROI) in research and development (R&D). The projected ROI has skyrocketed to 7.0 per cent in 2021, marking the highest level since 2014 (7.2 per cent). This notable increase of 4.3 percentage points from 2020 represents the most substantial annual rise since the inception of the study. Moreover, the forecasted average peak sales per asset have reached an impressive $521 million, the highest level in four years. This surge is significantly greater than the $422 million reported in 2020. The driving force behind this upswing is attributed, in part, to the optimistic sales forecasts for COVID-19 vaccinations and treatments that have received emergency approvals, making a considerable impact on the mass market. Notably, six out of the 15 compan...